Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

June 28th 2023

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Epcoritamab Elicits an ORR of 82% in Relapsed/Refractory Follicular Lymphoma

June 28th 2023

Epcoritamab elicited a confirmed overall response rate of 82% by independent review committee assessment in patients with relapsed or refractory follicular lymphoma who received 2 or more prior systemic treatments, which exceeded the prespecified threshold for efficacy in the phase 1/2 EPCORE NHL-1 trial.

Novel CD19xCD3 Bispecific Antibody May Expand Second-Line Options in Follicular Lymphoma

June 28th 2023

Ryan Jacobs, MD, expands on the initial efficacy and safety data seen with TNB-486, the need for more data on treatment-related CRS to improve toxicity management, and next steps planned for the investigation of this and other bispecific antibodies in relapsed/refractory follicular lymphoma.

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27th 2023

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.

Dr Gill on the Efficacy and Genomic Features of Ropeginterferon Alfa-2B in Myelofibrosis

June 27th 2023

Harry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis.

Quizartinib Plus Chemotherapy Improves EFS, RFS in Newly Diagnosed FLT3-ITD–Negative AML

June 27th 2023

Pau Montesinos, MD, PhD, discusses the preliminary results of the QUIWI trial, expands on the potential implications for the use of quizartinib plus chemotherapy in newly diagnosed patients with FLT3-ITD–negative acute myeloid leukemia, and details the next steps for this study and future research.

Long-Term ROSEWOOD Data Confirm Efficacy of Zanubrutinib Plus Obinutuzumab in R/R Follicular Lymphoma

June 27th 2023

The addition of zanubrutinib to obinutuzumab produced superior clinical activity, prolonged survival, and had a favorable toxicity profile compared with obinutuzumab alone in heavily pretreated patients with relapsed/refractory follicular lymphoma.

Outcomes Following Brexucabtagene Autoleucel Administered as an FDA-Approved Therapy for Adults with Relapsed/Refractory B-ALL

June 27th 2023

Greg Roloff, MD, reviews data on the outcomes of patients with relapsed/refractory B-ALL who received treatment with brexucabtagene autoleucel.

MB-106 Generates Responses in BTK Inhibitor–Refractory Waldenström Macroglobulinemia

June 26th 2023

The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor.

AZD4573 Elicits Responses in Relapsed/Refractory Peripheral T-cell Lymphoma

June 26th 2023

Single-agent treatment with the CDK9 inhibitor AZD4573 produced clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma.

Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL

June 26th 2023

Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Risk Stratification of MDS

June 26th 2023

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Factors in Selecting Treatment for Relapsed/Refractory DLBCL

June 26th 2023

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Diagnosing Myelodysplastic Syndromes (MDS)

June 26th 2023

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

NCCN Adds Epcoritamab to Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

June 23rd 2023

Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma, including patients with disease progression after transplant or CAR T-cell therapy, and as a category 2A preferred regimen for patients with histologic transformation of indolent lymphoma to DLBCL with no intention to proceed to transplant, including patients with disease progression after transplant or CAR T-cell therapy.

New and Anticipated Advances Across Hematologic Malignancies Necessitate Improved Navigation of Current Options

June 23rd 2023

John M. Burke, MD, expands on the use of novel BTK inhibitor regimens in mantle cell lymphoma, treatment sequencing challenges and other unmet needs in diffuse-large B-cell lymphoma, the evolution of management strategies for myeloproliferative neoplasms, and the potential influence of new and emerging therapeutics in chronic lymphocytic leukemia.

BrECADD Proves Noninferior to eBEACOPP in Advanced Classical Hodgkin Lymphoma

June 22nd 2023

The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.

FDA Issues Complete Response Letter to NDA for ADX-2191 in Primary Vitreoretinal Lymphoma

June 22nd 2023

The FDA has issued a complete response letter to the new drug application seeking the approval of ADX-2191 for the treatment of patients with primary vitreoretinal lymphoma.

Clinical Use of Luspatercept on Patients with Lower-risk MDS

June 22nd 2023

Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.

Frontline Treatment Options for Lower-Risk MDS

June 22nd 2023

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.